Skip to main content

Table 1 Characteristics of the seven selected studies

From: Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis

Author/year [Ref.]

Line of treatment

Bevacizumab dose

No. of patients

Median PFS (m)

Median OS (m)

ORR (%)

    

HTN vs. No HTN

HTN vs. No HTN

HTN vs. No HTN

Scartozzi M/2009[20]

First-line

5 mg/kg/2w

39

14.5 vs. 3.1

NA vs. 15.1

75% vs. 32%

Rebekah/2009[21]

First-line

NA

52

NA vs. NA

NA vs. NA

NA vs. NA

De Stefano/2011[19]

First-line

5 mg/kg/2w or 7.5 mg/kg/3w

74

15.1 vs. 8.3

35.5 vs. 26.7

84.6% vs. 42.6%

Osterlund P/2011[17]

First- or second-line

5 mg/kg/2w

101

10.5 vs. 5.3

25.8 vs. 11.7

52.6% vs. 45.5%

Horinouchi Y/2011[18]

First-line

NA

36

16.25 vs. 10

NA vs. NA

60% vs. 23.1%

Dewdney A/2011[22]

First-line

7.5 mg/kg/3w

45

NA vs. NA

NA vs. NA

71% vs. 78%

Tahover E/2013[16]

First- or second-line

2. 5 mg/kg/w

181

29.9 vs. 17.2

NA vs. 36.8

NA vs. NA

  1. ORR: Overall response rate; NA: Information not available; PFS: Progression-free survival; OS: Overall survival; HTN: Hypertension group; N0 HTN: No hypertension.